Losartan var i denne undersøgelse generelt veltålt, dokumenteret ved en seponeringsincidens på grund af bivirkninger svarende til placebos.
In this study losartan was generally well tolerated, as shown by a therapy discontinuation rate on account of adverse events that was comparable to the placebo group.